Cargando…
Reply to: The need for evidence‐based treatment decisions in spinal muscular atrophy type 0
Autores principales: | Mercuri, Eugenio, Tiberi, Eloisa, Costa, Simonetta, Pane, Marika, Priolo, Francesca, Romeo, Domenico, de Sanctis, Roberto, Tiziano, Danilo, Conti, Giorgio, Vento, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528451/ https://www.ncbi.nlm.nih.gov/pubmed/34546660 http://dx.doi.org/10.1002/acn3.51458 |
Ejemplares similares
-
Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020) -
Reply to Aljabali et al. Comment on “Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213”
por: Abdelazeem, Basel, et al.
Publicado: (2022) -
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?
por: Pera, Maria Carmela, et al.
Publicado: (2020) -
Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011) -
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening
por: Pane, Marika, et al.
Publicado: (2022)